Gapping up
In reaction to strong earnings/guidance: SWHC +7%, MZOR +4.6%, (Q4 guidance)
M&A news: BIN +4% (confirms it has commenced review of strategic alternatives), FCS +3.8% (determines revised unsolicited proposal from China Resources and Hua Capital of $21.70/share in cash would reasonably be expected to result in a 'Superior Proposal')
Select metals/mining stocks trading higher: HMY +5.7%, MT +2.7%, AG +2.3%, FCX +1.8%, GG +1.5%, VALE +1.3%, SLV +1.2%, RIO +1.1%, NEM +1.1%, GDX +0.9%, ABX +0.9%
Other news: UNIS +28.5% (cont strength), GBSN +11.7% (announces updates to the 2016 product roadmap and status for previously announced products and FDA submissions), IMMU +7.8% (issued new patent for additional claims under the patent family 'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'), EXEL +6.6% (announced 'positive' results from subgroup analyses of the meteor Phase 3 pivotal trial) CTIC +4.1% (CTI BioPharma and Baxalta submit NDA for Pacritinib), RPRX +3.8% (expects to meet with FDA to discuss 'Complete Response Letter' for enclomiphene NDA during)February 2016 GPRO +3.8% (presenting at Citi conf today), HIW +3.4% (has agreed to sell Country Club Plaza portfolio in Kansas City for $660 mln to a Taubman Centers (TCO) and The Macerich Company (MAC) joint venture), VCEL +2.8% (submits Biologics License Application to the FDA for MACI for the treatment of cartilage defects in the knee), MBLY +2.7% (GM exploring Mobileye advanced mapping with OnStar data)
Analyst comments: FSLR +4.3% (upgraded to Buy from Neutral at Goldman), JCP +1.9% (upgraded to Neutral from Sell at Citigroup), CLR +1.5% (upgraded to Buy from Neutral at BofA/Merrill), CLNE +1.4% (upgraded to Mkt Perform from Underperform at Raymond James), FMS +1.3% (upgraded to Buy from Neutral at UBS), RLYP +0.7% (initiated with a Buy at BTIG Research)
In reaction to strong earnings/guidance: SWHC +7%, MZOR +4.6%, (Q4 guidance)
M&A news: BIN +4% (confirms it has commenced review of strategic alternatives), FCS +3.8% (determines revised unsolicited proposal from China Resources and Hua Capital of $21.70/share in cash would reasonably be expected to result in a 'Superior Proposal')
Select metals/mining stocks trading higher: HMY +5.7%, MT +2.7%, AG +2.3%, FCX +1.8%, GG +1.5%, VALE +1.3%, SLV +1.2%, RIO +1.1%, NEM +1.1%, GDX +0.9%, ABX +0.9%
Other news: UNIS +28.5% (cont strength), GBSN +11.7% (announces updates to the 2016 product roadmap and status for previously announced products and FDA submissions), IMMU +7.8% (issued new patent for additional claims under the patent family 'Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity'), EXEL +6.6% (announced 'positive' results from subgroup analyses of the meteor Phase 3 pivotal trial) CTIC +4.1% (CTI BioPharma and Baxalta submit NDA for Pacritinib), RPRX +3.8% (expects to meet with FDA to discuss 'Complete Response Letter' for enclomiphene NDA during)February 2016 GPRO +3.8% (presenting at Citi conf today), HIW +3.4% (has agreed to sell Country Club Plaza portfolio in Kansas City for $660 mln to a Taubman Centers (TCO) and The Macerich Company (MAC) joint venture), VCEL +2.8% (submits Biologics License Application to the FDA for MACI for the treatment of cartilage defects in the knee), MBLY +2.7% (GM exploring Mobileye advanced mapping with OnStar data)
Analyst comments: FSLR +4.3% (upgraded to Buy from Neutral at Goldman), JCP +1.9% (upgraded to Neutral from Sell at Citigroup), CLR +1.5% (upgraded to Buy from Neutral at BofA/Merrill), CLNE +1.4% (upgraded to Mkt Perform from Underperform at Raymond James), FMS +1.3% (upgraded to Buy from Neutral at UBS), RLYP +0.7% (initiated with a Buy at BTIG Research)